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Abstract. The Global Program for Elimination of Lymphatic Filariasis calls for mass drug administration for endemic
populations outside of sub-Saharan Africa with a single dose of diethylcarbamazine (DEC) and albendazole (Alb)
annually for 4−6 years. Single-dose DEC/Alb dramatically reduces blood microfilaria (MF) counts, but most treated
subjects fail to completely clear MF after a single dose. A more effective regimen might reduce the number of years
required for elimination programs. We performed a randomized clinical trial in Egyptian adults with asymptomatic
microfilaremia to compare treatment with seven daily doses of oral DEC (6 mg/kg) and Alb (400 mg) with a single dose
of the same combination. We also studied the effect of re-treatment with single-dose DEC/Alb 12 months after the first
treatment course. Multi-dose DEC/Alb was significantly more effective than single-dose therapy for reducing and
clearing microfilaremia (mean reduction in MF/ml relative to pretreatment counts at 12 months, 99.6% versus 85.7%,
with complete clearance in 75% versus 23.1%). The two regimens had similar activity against adult filarial worms, as
indicated by serial ultrasound assessments. Neither regimen resulted in complete clearance of filarial antigenemia. There
was no difference in adverse events, which were mild to moderate. Blood microfilaria and parasite antigen clearance
rates increased following re-treatment. Multi-dose DEC/Alb may be a useful option for filariasis elimination programs,
especially in the first year (when enthusiasm for mass drug administration and coverage rates are high), to quickly reduce
community MF loads and transmission rates.
INTRODUCTION
Approximately 100 million people are infected with
Wuchereria bancrofti, a mosquito-transmitted nematode
parasite that causes deforming lymphatic filariasis in the trop-
ics.1 Improved therapies and diagnostic methods have led to
new thinking about lymphatic filariasis and the realization
that it should be possible to interrupt transmission and elimi-
nate this major public health problem by repeated, annual
cycles of mass drug administration (MDA) with new, single-
dose combination regimens.2–5
There is little doubt that combination therapy represents a
significant advance in treatment of filariasis.6 A single dose of
diethylcarbamazine with albendazole (DEC/Alb) results in
dramatic and sustained reductions in blood microfilaria (MF)
counts7 and is at least as effective as the previously widely
used regimen of 6 mg/kg of DEC daily for 12 days. Single-
dose therapy is easier to take and administer, and this should
improve compliance and treatment coverage rates in MDA
programs. However, clinical trial results and early experience
from MDA programs suggest that there is room for further
improvement in therapeutic regimens for MDA. For ex-
ample, two clinical trials have reported that a majority of
subjects had persistent low-level microfilaremia one year fol-
lowing treatment with a single dose of Alb with either DEC
or ivermectin.8,9 Other studies have shown that mosquitoes
fed on subjects with persistent, low-level microfilaremia fol-
lowing therapy ingest MF and produce infective filarial lar-
vae.10 The issue of treatment coverage must also be consid-
ered. No MDA program achieves complete coverage, and
80% coverage of eligible subjects (nonpregnant, more than
two years of age, with no serious acute or chronic illness) is
sometimes quoted as a goal for MDA programs;11 actual cov-
erage rates are often much lower than this.12 To some extent,
the problems of incomplete MF clearance and treatment cov-
erage can be solved by the recommended practice of continu-
ing MDA programs for 4−6 years in endemic areas. However,
early results from some MDA programs suggest that initial
enthusiasm for treatment, with high coverage rates, has been
difficult to sustain beyond the first years of the programs.13
Elimination programs could be shortened considerably by
availability of practical regimens that either killed all adult
filarial worms or completely cleared MF from the blood of
most MF carriers. Unfortunately, existing regimens do not
achieve either of these objectives.
Although the World Health Organization has recom-
mended single-dose DEC/Alb as a preferred combination for
repeated, annual MDA to hundreds of millions of people
residing in filariasis-endemic areas,3,14 relatively few patients
(mostly men in Sri Lanka) have been carefully studied to
assess the safety and efficacy of this combination for treat-
ment of bancroftian filariasis.7 In addition, no studies of
multi-dose DEC/Alb treatment or DEC/Alb re-treatment of
Bancroftian filariasis have been reported to date. Therefore,
the goals of this study were to restudy the safety and efficacy
of single-dose DEC/Alb in a different patient population, to
compare single-dose DEC/Alb therapy with seven daily doses
of the same regimen, and to study effects of re-treatment after
one year.
MATERIALS AND METHODS
Patient selection. Potential study participants with W. ban-
crofti microfilaremia were identified in the course of night
blood surveys for filariasis in an endemic village in Ba-
drasheen district, Giza Governate, approximately 45 km
south of Cairo, Egypt. Subjects who met inclusion criteria
(men and women, 18 years of age or older, with night blood
microfilaria counts > 80 MF/mL) were invited to participate
in the study. Written informed consent was required for par-
ticipation in the study, before pretreatment safety screening
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tests were performed. Subjects with evidence of clinical fila-
riasis by physical examination (hydrocele or lymphedema), a
history of treatment of filariasis in the past 12 months, dis-
ability (inability to work), or serious concurrent illness requir-
ing chronic medication were excluded from the study. Other
exclusions included acute febrile illness, renal disease (creat-
inine > 2 mg/dL), liver disease (serum bilirubin > 2 mg/dL or
alanine aminotransferase [ALT] > 80 IU/L), pregnancy, or
lactation.
Randomization and therapy. Eligible subjects were ran-
domly assigned to treatment groups with block stratification
for sex and blood microfilaria count. The trial was not
blinded. Study subjects were treated with either a single oral
dose of 6 mg/kg of diethylcarbamazine citrate (Pharmamed,
Zejtun, Malta) plus 400 mg of albendazole (GlaxoSmithKline,
Uxbridge, United Kingdom) or with the same medications
daily for seven days. All treatment was directly observed by
study personnel.
End points and sample size considerations. The primary
endpoint for this study was predefined to be the rate of com-
plete clearance of microfilaremia 12 months after treatment
(defined as zero MF in 1 mL of venous blood collected at
night), and the study was powered for this end point. This end
point was chosen because complete MF clearance is an im-
portant goal for filariasis elimination programs that aim to
interrupt transmission of the infection. We expected 25% of
subjects to clear MF 12 months after treatment with single-
dose Alb/DEC (based on prior studies).8,9 We hypothesized
that the seven-day treatment would completely clear MF in
75% of the subjects. This would be a biologically and epide-
miologically significant difference. We needed 18 evaluable
subjects (with follow-up at 12 months after treatment) per
group to have 90% power to detect a significant difference
(P < 0.05) between the treatment groups. Therefore, we de-
cided to enroll at least 25 subjects per treatment group to
allow for some dropouts. We also designated complete cure
(defined as complete clearance of microfilaremia and filarial
antigenemia 12 months after treatment) as a predefined sec-
ondary end point for the study. The study protocol specified
that group differences would be assessed based on an inten-
tion to treat analysis.
Tests for W. bancrofti infection. Venous blood samples
were collected between the hours of 9:00 PM and 1:00 AM
before and after treatment for parasitology and serology stud-
ies. Microfilariae were detected by membrane filtration (5
M; Nuclepore Corp., Pleasanton, CA) of 1 mL of venous
blood and microscopic examination of stained filters. Filarial
antigenemia, a marker for adult worm infection intensity, was
detected in the field with finger prick blood samples with the
AMRAD ICT Filariasis Test (AMRAD ICT, French’s For-
est, New South Wales, Australia) according to the manufac-
turer’s instructions. This test is a rapid format immunochro-
matography “card test”.15 Card test results were read visually
in the field after 15 minutes and reviewed the next day in the
laboratory. Equivocal card results were considered to be
negative.
Ultrasound studies. Effects of therapy on adult worms were
also directly assessed by ultrasound as previously described.16
The sonologist was blinded with regard to treatment group
assignments. Ultrasound findings after treatment were com-
pared with pretreatment results to assess loss of motile filarial
worms.17 The primary end point for this sub-study was pre-
defined to be loss of all motile worms in subjects who had
motile worms before therapy. The secondary end point was
the percentage decrease (by group) in the number of foci (or
“nests”) observed with motile adult filarial worms.
Incidence. Prior studies showed that MF incidence in the
study area was very low in recent years (less than 1% per
year).18 In addition, all endemic areas in Egypt (including our
study area) were mass-treated with DEC/Alb approximately
one month after our subjects were treated in this study.
Therefore, the data analysis plan for this study assumed that
there were no incident infections during the follow-up period.
Assessment of adverse events (AEs). Study personnel vis-
ited subjects in their homes on days 2, 7, and 14, at 4 weeks,
and 3 months after the first treatment dose to record the
presence and severity of AEs and to provide symptomatic
treatment of AEs. Complete blood counts, urinalysis, and
serum bilirubin, ALT, and creatinine tests were performed
one and four weeks after treatment. A pre-printed toxicity
table, modified for the study from a standard reference,19 was
used to grade the severity of AEs.
Re-treatment. All subjects were treated with a single oral
dose of 6 mg/kg of DEC and 400 mg of Alb one year after the
first round of treatment. Adverse event monitoring following
re-treatment was performed on days 2 and 7 after treatment.
Blood samples were collected 6 and 12 months after re-
treatment to assess the effects of re-treatment on MF counts
and filarial antigenemia.
Ethical clearance. This study was reviewed and approved
by institutional review boards at Washington University
School of Medicine and at Ain Shams University. The project
was also monitored by an independent data safety and moni-
toring board (Division of Microbiology and Infectious Dis-
eases, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, Bethesda, MD USA). The
funding source also reviewed the study protocol but had no
other role in the project.
Data analysis. Database management and statistical analy-
ses were performed with a statistical software package (SPSS,
Chicago, IL). Geometric mean MF counts were calculated by
adding 1 to MF counts before log transformation of the data
and subtracting 1 from the antilog of the mean of the log-
transformed data. Relative MF levels (expressed as % of the
pretreatment level) were calculated for each subject by divid-
ing post-treatment MF counts by the pretreatment value and
multiplying by 100. Proportions were compared by chi-square
analysis or Fisher’s exact test (two-tailed). The Mann-
Whitney U test was used to assess the significance of group
differences for continuous variables. We also performed a
mixed models analysis with subject as the random effect to
assess overall changes in relative MF levels and MF clearance
rates between treatment groups over time, controlling for age,
sex, and baseline microfilaria count.20
RESULTS
Treatment assignment and follow-up. Fifty-eight eligible
subjects consented to participate in the study. Pretreatment
clinical and laboratory parameters for the treatment groups
are summarized in Table 1. The two groups were comparable
in terms of age, sex, and infection intensity. All subjects com-
pleted the assigned therapy in August 2000. Cooperation with
follow-up was excellent ( 93% at all time points through 12
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months after treatment and 86% at 24 months). One subject
(a female in the single-dose treatment group) refused blood
draws after the one week post-treatment time point. She was
followed clinically and included in the assessment of adverse
events. Eleven subjects received an extra dose of DEC/Alb
approximately one month after they received the study treat-
ment. Six of these subjects were in the multi-dose treatment
group, and five were in the single-dose group. This extra
treatment dose was provided by government health officials
as part of the Egypt’s National Filariasis Elimination Pro-
gram. Results presented below represent an intention-to-treat
analysis, as stipulated by our study protocol. However, essen-
tially the same results were obtained when the analysis was
restricted to subjects who did not receive the extra treatment
dose.
Effects of therapy on microfilaremia. Microfilaria counts
decreased dramatically in both treatment groups by one
month after therapy, and these decreases were sustained until
subjects were re-treated at 12 months (Table 2). Decreases in
MF counts (Figure 1, top panel) and rates of complete MF
clearance (Figure 1, bottom panel) were significantly greater
in the multi-dose treatment group at all times after treatment.
A mixed models analysis of relative MF counts over time
with subject as the random effect revealed highly significant
effects of treatment group (P < 0.001) and baseline MF count
(P < 0.001). Age (P  0.28) and sex (P  0.83) were not
significant factors influencing relative MF after treatment. A
mixed generalized linear model was also used to analyze MF
clearance (also setting subject as the random effect). Again,
treatment group (P < 0.001) and baseline MF count (P 
0.011) were significant factors while sex (P  0.593) and age
(P  0.69) were not significant.
Effects of therapy on adult worm viability. Fifty-six of 58
subjects (96.6%) had filarial antigenemia detectable by the
ICT antigen card test prior to treatment. Antigen lines in card
tests tended to be less intense with post-treatment blood
samples. Six of 52 subjects (11.5%, 3 in each treatment group)
with positive ICT antigen card test results before treatment
had negative card test results 12 months after treatment.
Motile adult filarial worms were detected by ultrasound in
a majority of subjects prior to treatment (Table 1). This find-
ing was more common in men than in women (28 of 36, [78%]
versus 5 of 22 [22.7%]). Most worms seen in men were located
in dilated scrotal lymphatic vessels. Worms in women were
located in dilated lymphatic vessels draining the extremities.
Inactivation of all visible worm nests was achieved 12 months
after treatment in 12 of 15 subjects tested on both occasions in
the single-dose treatment group and in 12 of 14 subjects in the
multi-dose group. A majority of motile worm nests were in-
activated in both treatment groups by 12 months after treat-
ment (overall 57 of 63, [90.5%]; single dose, 27 of 31 [87.1%];
TABLE 1






Age, mean (SE) 36.7 (16.1) 30.4 (10.5) 0.14†
Sex 18 M, 10 F 18 M, 12 F 0.95‡
GM MF/mL (range) 359.1 (90–3,720) 399.9 (100–4,531) 0.72†
Presence of motile
adult worms by US 16/28 (57.1%) 17/30 (56.7%) 0.97‡
Filarial antigenemia
(card test) 27/28 (96.4%) 29/30 (96.7%) 1.00‡
* GM  geometric mean; MF  microfilariae; US  ultrasound.
† Mann-Whitney test.
‡ By chi-square analysis (Fisher’s exact test for filarial antigenemia).
TABLE 2
Effect of diethylcarbamazine/albendazole (DEC/Alb) treatment* on blood microfilaria counts† by group
Pre-treatment 1 Month 3 Months 6 Months 9 Months 12 Months 18 Months 24 Months
Single dose 359.1 (90–3,720) 58.3 (0–820) 31.3 (0–1,300) 37.0 (0–700) 18.4 (0–843) 14.4 (0–1,250) 5.0 (0–117) 2.4 (0–182)
Multidose 399.9 (100–4,531) 0.9 (0–17) 0.6 (0–19) 1.0 (0–17) 0.5 (0–20) 0.6 (0–93) 0.3 (0–122) 0.2 (0–70)
P‡ 0.715 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.003
* Subjects were treated with single-dose or multi-dose DEC/Alb at time zero and re-treated with single-dose DEC/Alb 12 months later.
† Data shown are geometric means (range).
‡ By Mann-Whitney U test.
FIGURE 1. Top, Effects of single dose (circles) or multi-dose (tri-
angles) diethylcarbamazine with albendazole on blood microfilaria
counts relative to pretreatment counts. Data shown are the mean ±
SE. Differences at all time points after treatment are statistically
significant (P < 0.01). Bottom, Efficacy of these regimens for achiev-
ing complete clearance of microfilaremia. Differences at all time
points after treatment are statistically significant (P < 0.01). Microfi-
laria clearance was achieved 12 months after treatment (the pre-
defined primary endpoint for the study) in 6 (23.1%) of 26 subjects in
the single-dose group (95% confidence interval [CI]  9.8−44.1%)
and in 21 (75%) of 28 subjects in the multi-dose group (95% CI 
54.8−88.6%).
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multi-dose 30 of 31 [93.8%]; group difference not statistically
significant).
Adverse events. Adverse events of mild-to-moderate sever-
ity were common following therapy in both treatment groups,
with no significant difference in event frequencies between
the two treatment groups (Table 3). The most frequent ad-
verse events observed were fever, headache, and myalgia.
These symptoms usually resolved within 2−3 days. Subjective
fever, myalgia, and headache were more common in people
with high blood MF counts, and headache was significantly
more common in women than in men. Serum creatinine, bil-
irubin, and ALT levels were stable in all patients tested one
and four weeks following treatment. Scrotal discomfort
peaked at one week after treatment, and one man had per-
sistent, mild scrotal discomfort four weeks after treatment.
No severe or serious adverse events were observed; indeed,
all adverse events were scored as grade 1 or 2 events. That is
to say, no AEs were severe enough to interfere with activities
of daily living.
Re-treatment results. Cumulative effects of both rounds of
treatment on MF are shown by treatment group in Figure 1
(18 and 24 month time points). Note that MF reduction and
clearance rates 12 months after multi-dose DEC/Alb were
superior to those seen 12 months after two annual single-dose
treatments. All but one of the subjects in the multi-dose
group in year one cleared MF by 12 months after re-treatment
with single-dose DEC/Alb.
Twenty-seven of the re-treated subjects had persistent mi-
crofilaremia (geometric mean 104.3 MF/mL, range 
1−1,250) at the12-month time point, just prior to re-
treatment. Mean reductions in MF count (relative to the 12
month levels) for 25 subjects studied 6 and 12 months follow-
ing re-treatment were 67% (SE 9%) and 89% (SE 4%),
respectively. Total MF clearance was achieved 6 and 12
months following re-treatment in 9 (36%) of 25 and 15 (60%)
of 25 of these subjects, respectively.
Ultrasound results showed further clearance of adult
worms following re-treatment. Five subjects had motile
worms visible 12 months after the first round of treatment
(one nest in each subject). Two of these subjects had persis-
tent motile worms visible 12 months after re-treatment (one
subject in each of the original treatment groups). The 24-
month data show that two rounds of treatment inactivated 56
of 58 worm nests (96.6%) in 25 subjects who had motile
worms pretreatment and who were retested at 24 months.
Twenty-three of these subjects (92%) had total inactivation of
motile worms.
Many subjects had complete clearance of filarial antigen-
emia by the ICT card test 12 months after re-treatment (11 of
22 originally seropositive subjects treated with single-dose
DEC/Alb in year 1; 9 of 26 originally seropositive subjects
treated with multi-dose DEC/Alb in year 1, difference in
clearance rates is not significant). Interestingly, only 2 of 20
subjects who cleared antigenemia had persistent microfilare-
mia (range  20−26 MF/mL) 12 months after re-treatment,
while 8 of 28 subjects with persistent antigenemia at this time
had persistent microfilaremia (range  4−182 MF/ml). This
difference in MF persistence rates was not statistically signifi-
cant (P  0.16, by Fisher’s exact test).
Adverse events in the week following re-treatment of 51
subjects (33 men and 18 women) were greatly reduced com-
pared with those observed following the first round (fever
9%, headache 5%, myalgia 7%, scrotal pain one week after
treatment 0%) (P < 0.02, by Fisher’s exact test).
DISCUSSION
This study has generated significant new information on the
use of combination DEC/Alb therapy for bancroftian filaria-
sis. Single-dose DEC/Alb was highly effective for reducing
blood MF counts, with a 96% reduction in geometric mean
MF/mL 12 months after treatment. However, as in prior stud-
ies, most single-dose DEC/Alb recipients had persistent, low-
level microfilaremia 12 months after treatment. Multi-dose
DEC/Alb therapy was much more effective than single-dose
treatment for reducing and clearing MF. Entomology results
will be reported separately, but parallel results favoring multi-
dose treatment were observed in studies of the effects of
DEC/Alb therapy on MF ingestion and production of infec-
tive larvae by mosquitoes fed on these subjects.
In contrast to MF results, single and multi-dose DEC/Alb
seemed to have similar partial killing effects on adult filarial
worms, based on direct visualization of adult worms by ultra-
sound and reductions in the degree of positivity in filarial
antigen card test results. The ultrasound data suggest that a
majority of adult worms were killed by the first round of
DEC/Alb therapy. However, antigen test results suggest that
some adult parasites survived the first round of treatment
with these regimens in most subjects.
Single-dose and multi-dose DEC/Alb therapy were well
tolerated by men and women, and study subjects did not ex-
perience severe or serious adverse events. It is possible that a
larger study might have identified differences in AEs between
the study groups; our study was not powered to detect subtle
group differences in rates or severity of AEs. Similarly, our
results do not guarantee that no serious AEs would be seen in
large-scale treatment programs with these regimens. While it
is not practical to provide active follow-up for all participants
in MDA programs, such programs must provide a system for
detection of AEs and for referral of subjects for evaluation
TABLE 3
Adverse events following diethylcarbamazine/albendazole therapy by
treatment group*
Symptom Day 2 Week 1 Week 2 Week 4
Single dose
n  28 n  27 n  27 n  28
Fever 8 (29)† 0 (0) 0 (0) 0 (0)
Headache 7 (25) 2 (7) 0 (0) 0 (0)
Vomiting 1 (4) 1 (4) 0 (0) 0 (0)
Myalgia 7 (25) 3 (11) 0 (0) 0 (0)
Scrotal pain† 2 (11) 3 (17) 1 (6) 0 (0)
Multidose
n  30 n  30 n  29 n  30
Fever 8 (27) 0 (0) 0 (0) 0 (0)
Headache 10 (33) 3 (10) 0 (0) 0 (0)
Vomiting 2 (7) 0 (0) 0 (0) 0 (0)
Myalgia 11 (37) 0 (0) 0 (0) 0 (0)
Scrotal pain† 1 (6) 5 (28) 3 (17) 1 (6)
* Differences in adverse events by treatment group were not statistically significant. Data
shown are numbers of subjects (%).
† Scrotal pain (%) in men only.
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and treatment of AEs following MDA.14 This provides relief
to those who experience AEs after treatment, and it is an
important public relations tool to help ensure continued co-
operation with MDA over the years needed to achieve fila-
riasis elimination.
Re-treatment was effective at further reducing MF counts
in people with residual microfilaremia following the first
round of treatment; similar results have been reported after
DEC/Alb re-treatment of patients with brugian filariasis.21
Thus, there was no evidence that subjects who failed to clear
MF after the first round of treatment harbored resistant para-
sites. It is interesting that many subjects (20 of 48 subjects who
were originally seropositive [41.67%]) had negative filarial
antigen test results 12 months following re-treatment with
DEC/Alb. This rate of antigen clearance is much higher than
those observed in prior studies of repeated treatment with
DEC or ivermectin.22,23 We believe that complete clearance
of parasite antigenemia usually indicates clearance of all adult
filarial worms. Although occasional subjects who cleared fi-
larial antigenemia had persistent, low-level microfilaremia,
our results suggest that it may be useful to follow serial filarial
antigen prevalence rates as a means of monitoring the effect
of MDA on filariasis endemicity in communities and regions.
Our study has several other potentially important implica-
tions for the Global Program for Elimination of Lymphatic
Filariasis (GPELF). First, our results support the main strat-
egy of GPELF, because they suggest that MDA with repeated
annual doses of DEC/Alb could lead to elimination of lym-
phatic filariasis in some endemic areas. Our results also sug-
gest that multi-dose treatment may be a useful option for
filariasis elimination programs, since this can be more effec-
tive than single-dose treatment of rapidly reducing and clear-
ing microfilaremia. Seven-day treatment courses may not be
practical for MDA, and additional research is needed to study
shorter multi-dose regimens. Multi-dose therapy might be es-
pecially useful in areas with high baseline infection preva-
lence rates and intensities and high transmission rates. Fila-
riasis elimination program coordinators working in such areas
might choose to use multi-dose MDA in the first year of
elimination programs, when enthusiasm for MDA and cover-
age rates are high. Multi-dose MDA is likely to quickly re-
duce community MF loads and transmission rates to levels
that can be further reduced to zero by subsequent rounds of
single-dose treatment. This approach might reduce the num-
ber of years of MDA required for filariasis elimination.
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